Showing 1091-1100 of 19239 results for "".
Truths and Myths About Facial Danger Zones When Injecting Soft Tissue Fillers
https://reachmd.com/programs/modern-aesthetics/truths-and-myths-about-facial-danger-zones-when-injecting-soft-tissue-fillers/39264/Despite the current dip in demand for aesthetic treatments with soft tissue fillers, minimally invasive procedures remain popular and are widely accepted as alternatives to facial surgery.Gut Microbiota and Pediatric MS: New Insights Into Potential Disease Drivers
https://reachmd.com/programs/neurofrontiers/gut-microbiota-and-pediatric-ms-new-insights-into-potential-disease-drivers/26487/A new study investigating the relationship between gut microbiota composition and pediatric-onset multiple sclerosis (MS) offers evidence that a depletion of short-chain fatty acid (SCFA) producers may play a role in the disease's pathogenesis. Discover how these findings have the potential to inforTreatment Options for Invasive Fungal Infections: Why They Don't Always Work
https://reachmd.com/programs/cme/treatment-options-for-invasive-fungal-infections-why-they-dont-always-work/14809/Treatment options for invasive fungal infections are limited, but that’s changing. Find out what’s on the horizon and how to best fight the fungus.IBD and Biosimilars: What Healthcare Professionals Need to Know
https://reachmd.com/programs/gi-insights/ibd-and-biosimilars-what-healthcare-professionals-need-to-know/13835/Do you know how the approval of biosimilars will impact the treatment of inflammatory bowel disease? Hear from our experts and stay up to date!Amyloid and Tau in Alzheimer’s Disease: Insights into Disease Progression
https://reachmd.com/programs/medical-industry-feature/amyloid-tau-alzheimers-disease-progression/37874/The prevalence of dementia is projected to almost double every 20 years.1 Alzheimer’s disease (AD) is the most common cause of dementia,2 making early diagnosis and management increasingly important. Based on our current understanding of its pathology, AD is an amyloid driven tauopathy3 with biomarkRedefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.A New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion
https://reachmd.com/programs/cme/a-new-paradigm-in-igan-managementadvancing-clinical-practice-in-the-era-of-therapeutic-expansion/54415/On-demand webcast on the latest advances in diagnosing and managing patients with IgA nephropathy (IgAN), including the current data on new and emerging IgAN therapies.Management Approaches in Radiographically Isolated Syndrome
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/management-approaches-in-radiographically-isolated-syndrome/32089/How best to define radiographically isolated syndrome has been the subject of debate; challenges in determining the best management approach remain.From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Imaging in the Diagnosis and Management of ADPKD
https://reachmd.com/programs/cme/imaging-in-the-diagnosis-and-management-of-adpkd/13876/This Expert Exchange webcast is designed to help improve clinicians’ understanding of the role radiologic imaging plays in the diagnosis and management of ADPKD. This activity is not available for continuing education credit.